TehTarik的个人主页 - 老虎社区

TehTarik

暂无个人介绍

IP属地：未知

3关注

1粉丝

0主题

0勋章

2022-01-01

nice

抱歉，原内容已删除

2022-01-01

wow

抱歉，原内容已删除

2022-01-01

great!

抱歉，原内容已删除

2021-06-25

like

抱歉，原内容已删除

2021-06-25

wah

抱歉，原内容已删除

2021-06-24

like

抱歉，原内容已删除

2021-06-24

Nioo

抱歉，原内容已删除

2021-06-24

like

抱歉，原内容已删除

2021-06-22

wow

If You Thought These 2 Big Nasdaq Winners Were Done, Think Again

2021-06-22

nice

抱歉，原内容已删除

2021-06-22

man

抱歉，原内容已删除

2021-06-22

wow

抱歉，原内容已删除

2021-06-22

like!

"This Is Not A Temporary Situation": The Global Chip Shortage Will Continue To Push Prices Higher

2021-06-21

like

抱歉，原内容已删除

2021-06-21

like

抱歉，原内容已删除

2021-06-20

like!

抱歉，原内容已删除

2021-06-20

:0

抱歉，原内容已删除

2021-06-18

good!!

抱歉，原内容已删除

2021-06-18

:00

Orphazyme shares tumbled more than 60% in pre-market trading

2021-06-18

like n comment!

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3573902637171983","uuid":"3573902637171983","gmtCreate":1611756144058,"gmtModify":1611756144058,"name":"TehTarik","pinyin":"tehtarik","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":1,"headSize":3,"tweetSize":20,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-2","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"资深虎友","description":"加入老虎社区1000天","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.10.25","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"35ec162348d5460f88c959321e554969-1","templateUuid":"35ec162348d5460f88c959321e554969","name":"精英交易员","description":"证券或期货账户累计交易次数达到30次","bigImgUrl":"https://static.tigerbbs.com/ab0f87127c854ce3191a752d57b46edc","smallImgUrl":"https://static.tigerbbs.com/c9835ce48b8c8743566d344ac7a7ba8c","grayImgUrl":"https://static.tigerbbs.com/76754b53ce7a90019f132c1d2fbc698f","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"60.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":11,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":692251955,"gmtCreate":1641003795174,"gmtModify":1641003795174,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692251955","repostId":"2195448557","repostType":4,"isVote":1,"tweetType":1,"viewCount":2601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253758,"gmtCreate":1641003778376,"gmtModify":1641003778376,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253758","repostId":"1114332157","repostType":4,"isVote":1,"tweetType":1,"viewCount":1952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253123,"gmtCreate":1641003752634,"gmtModify":1641003752726,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253123","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":122154699,"gmtCreate":1624606940611,"gmtModify":1631890740816,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122154699","repostId":"2146027771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154864,"gmtCreate":1624606929858,"gmtModify":1631890740830,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/122154864","repostId":"1169758731","repostType":4,"isVote":1,"tweetType":1,"viewCount":1330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121269818,"gmtCreate":1624465750834,"gmtModify":1631890740844,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121269818","repostId":"1127255730","repostType":4,"isVote":1,"tweetType":1,"viewCount":2927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285710,"gmtCreate":1624465639130,"gmtModify":1631890740866,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"Nioo","listText":"Nioo","text":"Nioo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121285710","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":2235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285619,"gmtCreate":1624465614931,"gmtModify":1631890740868,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121285619","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027708,"gmtCreate":1624346334604,"gmtModify":1631890740882,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027708","repostId":"1186855284","repostType":4,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<blockquote>\n On a strong day for the Nasdaq, two highfliers stood out.\n</blockquote>\n<p>Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p>\n<p>It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p>\n<p><b>More moves for Moderna and BioNTech</b></p>\n<p>Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p>\n<p>The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p>\n<p>In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p>\n<p>More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p>\n<p><b>Will existing vaccines be enough?</b></p>\n<p>The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p>\n<p>For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p>\n<p>If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 14:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq  was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027304,"gmtCreate":1624346321408,"gmtModify":1631890740897,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129027304","repostId":"2145033651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027014,"gmtCreate":1624346306138,"gmtModify":1631890740911,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"man","listText":"man","text":"man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027014","repostId":"1161295709","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024568,"gmtCreate":1624346293054,"gmtModify":1631890740926,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129024568","repostId":"1139414035","repostType":4,"isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024813,"gmtCreate":1624346278732,"gmtModify":1631890740940,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129024813","repostId":"1136223229","repostType":4,"repost":{"id":"1136223229","kind":"news","pubTimestamp":1624345984,"share":"https://www.laohu8.com/m/news/1136223229?lang=&edition=full","pubTime":"2021-06-22 15:13","market":"us","language":"en","title":"\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1136223229","media":"zerohedge","summary":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same","content":"<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p>\n<p>Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p>\n<p>The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p>\n<p><img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p>\n<p>Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p>\n<p>Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p>\n<p>Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p>\n<p>Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p>\n<p><img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p>\n<p>The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p>\n<p>Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 15:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯"},"source_url":"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136223229","content_text":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.\nErgo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.\nThe report notes that items like one ASUS laptop that formerly cost $900 now costs $950. An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".\nDell Technologies Inc. Chief Financial Officer Thomas Sweet recently said: “As we think about component cost increases, we’ll adjust our pricing as appropriate.”\nBernstein analyst Toni Sacconaghimade excuses for HPexplained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.\nVincent Roche, the CEO of chip maker Analog Devices Inc., commented: “We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”\nHock Tan, CEO of Broadcom Inc., simply noted: “We see cost inflation.”\nDigi-Key Electronics has also raised prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".Certain components now cost 40% more than they used to, according to David Stein, the company’s vice president of global supplier management.\n\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the Journalnotes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".\nThe median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to Supplyframe Inc.\nDale Ford, the chief analyst at the Electronic Components Industry Association, concluded: “Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167303200,"gmtCreate":1624245214400,"gmtModify":1631892937410,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167303200","repostId":"2145707918","repostType":4,"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167309877,"gmtCreate":1624245184099,"gmtModify":1631892937423,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167309877","repostId":"2145700634","repostType":4,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164045216,"gmtCreate":1624162915335,"gmtModify":1631892937432,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164045216","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164042708,"gmtCreate":1624162897804,"gmtModify":1631892937445,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":0","listText":":0","text":":0","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164042708","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166652695,"gmtCreate":1624007827517,"gmtModify":1631892937456,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"good!!","listText":"good!!","text":"good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166652695","repostId":"1164089282","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664750,"gmtCreate":1624006893770,"gmtModify":1631892937476,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":00","listText":":00","text":":00","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664750","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://www.laohu8.com/m/news/1142916683?lang=&edition=full","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 16:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664632,"gmtCreate":1624006870226,"gmtModify":1631892937482,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like n comment!","listText":"like n comment!","text":"like n comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664632","repostId":"2144005727","repostType":4,"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":129024813,"gmtCreate":1624346278732,"gmtModify":1631890740940,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":6,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129024813","repostId":"1136223229","repostType":4,"repost":{"id":"1136223229","kind":"news","pubTimestamp":1624345984,"share":"https://www.laohu8.com/m/news/1136223229?lang=&edition=full","pubTime":"2021-06-22 15:13","market":"us","language":"en","title":"\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher","url":"https://stock-news.laohu8.com/highlight/detail?id=1136223229","media":"zerohedge","summary":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same","content":"<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.</p>\n<p>Ergo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.</p>\n<p>The report notes that items like one ASUS laptop that formerly cost $900 now costs $950.&nbsp;An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".</p>\n<p><img src=\"https://static.tigerbbs.com/74a5e52dd05c247a48e848e3072dfd5f\" tg-width=\"500\" tg-height=\"629\">Dell Technologies Inc. Chief Financial Officer Thomas Sweet recently said:&nbsp;<b>“As we think about component cost increases, we’ll adjust our pricing as appropriate.”</b></p>\n<p>Bernstein analyst&nbsp;Toni Sacconaghi<s>made excuses for HP</s>explained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.</p>\n<p>Vincent Roche, the CEO of chip maker Analog Devices Inc., commented:&nbsp;“We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”</p>\n<p>Hock Tan, CEO of Broadcom Inc., simply noted:&nbsp;“We see cost inflation.”</p>\n<p>Digi-Key Electronics has also raised&nbsp;prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".<b>Certain components now cost 40% more than they used to, according to&nbsp;David Stein, the company’s vice president of global supplier management.</b></p>\n<p><img src=\"https://static.tigerbbs.com/f27bfd7c03cafd2548e8458383d9d92b\" tg-width=\"500\" tg-height=\"651\">\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the&nbsp;<i>Journal</i>notes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".</p>\n<p>The median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to&nbsp;Supplyframe Inc.</p>\n<p>Dale Ford, the chief analyst at the Electronic Components Industry Association, concluded:&nbsp;<b>“Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”</b></p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n\"This Is Not A Temporary Situation\": The Global Chip Shortage Will Continue To Push Prices Higher\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 15:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher><strong>zerohedge</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the ...</p>\n\n<a href=\"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{".SPX":"S&P 500 Index",".IXIC":"NASDAQ Composite","SPY":"标普500ETF",".DJI":"道琼斯"},"source_url":"https://www.zerohedge.com/markets/not-temporary-situation-global-chip-shortage-will-continue-push-prices-higher","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1136223229","content_text":"The ongoing global semiconductor shortage is causing prices of electronics to rise while at the same time pressuring suppliers and material providers to continue raising prices. In the midst of the shortage, demand for consumer electronics has continued to rocket higher.\nErgo, industry officials believe that the increases are likely to continue, according to a newWall Street Journal report. The effects can be easily seen in consumer electronics.\nThe report notes that items like one ASUS laptop that formerly cost $900 now costs $950. An HP Chromebook laptop that used to cost $220 has seen its price rise to $250. In fact, HP has raised consumer PC prices by 8% and printer prices by more than 20% in just the short span of a year. the company's CEO blames the rise in prices on \"component shortages\".\nDell Technologies Inc. Chief Financial Officer Thomas Sweet recently said: “As we think about component cost increases, we’ll adjust our pricing as appropriate.”\nBernstein analyst Toni Sacconaghimade excuses for HPexplained the price hikes by saying they reflected an absence of usual discounts, instead of all-out price increases.\nVincent Roche, the CEO of chip maker Analog Devices Inc., commented: “We’re not taking advantage of this cycle to do anything on pricing, other than where we are paying more for the additional supply that we’ve got to get on board. We’re passing that on.”\nHock Tan, CEO of Broadcom Inc., simply noted: “We see cost inflation.”\nDigi-Key Electronics has also raised prices of semiconductor-related components by roughly 15% this year. They blame it on \"pressures from the supply crunch\".Certain components now cost 40% more than they used to, according to David Stein, the company’s vice president of global supplier management.\n\"Contract prices for computer memory have risen about 34% since the beginning of last year,\" the Journalnotes, calling the rising prices \"part of broader uptick in inflation in the U.S. economy\".\nThe median price of the top 20 bestselling microcontrollers is up by more than 12% since the middle of last year, according to Supplyframe Inc.\nDale Ford, the chief analyst at the Electronic Components Industry Association, concluded: “Raw-material costs have gone up more recently, and I think people are now saying this is not a temporary situation. Price increases are going to be durable.”","news_type":1,"symbols_score_info":{".DJI":0.9,".IXIC":0.9,".SPX":0.9,"SPY":0.9}},"isVote":1,"tweetType":1,"viewCount":380,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154864,"gmtCreate":1624606929858,"gmtModify":1631890740830,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wah","listText":"wah","text":"wah","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/122154864","repostId":"1169758731","repostType":4,"isVote":1,"tweetType":1,"viewCount":1330,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285619,"gmtCreate":1624465614931,"gmtModify":1631890740868,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/121285619","repostId":"2145531099","repostType":4,"isVote":1,"tweetType":1,"viewCount":1145,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027304,"gmtCreate":1624346321408,"gmtModify":1631890740897,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/129027304","repostId":"2145033651","repostType":4,"isVote":1,"tweetType":1,"viewCount":1781,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129024568,"gmtCreate":1624346293054,"gmtModify":1631890740926,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":4,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129024568","repostId":"1139414035","repostType":4,"isVote":1,"tweetType":1,"viewCount":465,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":122154699,"gmtCreate":1624606940611,"gmtModify":1631890740816,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/122154699","repostId":"2146027771","repostType":4,"isVote":1,"tweetType":1,"viewCount":1132,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167303200,"gmtCreate":1624245214400,"gmtModify":1631892937410,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167303200","repostId":"2145707918","repostType":4,"isVote":1,"tweetType":1,"viewCount":442,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164045216,"gmtCreate":1624162915335,"gmtModify":1631892937432,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like!","listText":"like!","text":"like!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164045216","repostId":"1161408410","repostType":4,"isVote":1,"tweetType":1,"viewCount":267,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166652695,"gmtCreate":1624007827517,"gmtModify":1631892937456,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"good!!","listText":"good!!","text":"good!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/166652695","repostId":"1164089282","repostType":4,"isVote":1,"tweetType":1,"viewCount":295,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692253758,"gmtCreate":1641003778376,"gmtModify":1641003778376,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253758","repostId":"1114332157","repostType":4,"isVote":1,"tweetType":1,"viewCount":1952,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":692253123,"gmtCreate":1641003752634,"gmtModify":1641003752726,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"great!","listText":"great!","text":"great!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692253123","repostId":"2200744536","repostType":4,"isVote":1,"tweetType":1,"viewCount":2021,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":121269818,"gmtCreate":1624465750834,"gmtModify":1631890740844,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121269818","repostId":"1127255730","repostType":4,"isVote":1,"tweetType":1,"viewCount":2927,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":129027014,"gmtCreate":1624346306138,"gmtModify":1631890740911,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"man","listText":"man","text":"man","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027014","repostId":"1161295709","repostType":4,"isVote":1,"tweetType":1,"viewCount":354,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":167309877,"gmtCreate":1624245184099,"gmtModify":1631892937423,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like","listText":"like","text":"like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/167309877","repostId":"2145700634","repostType":4,"isVote":1,"tweetType":1,"viewCount":415,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":164042708,"gmtCreate":1624162897804,"gmtModify":1631892937445,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":0","listText":":0","text":":0","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/164042708","repostId":"1183124175","repostType":4,"isVote":1,"tweetType":1,"viewCount":405,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664750,"gmtCreate":1624006893770,"gmtModify":1631892937476,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":":00","listText":":00","text":":00","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664750","repostId":"1142916683","repostType":4,"repost":{"id":"1142916683","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1624003342,"share":"https://www.laohu8.com/m/news/1142916683?lang=&edition=full","pubTime":"2021-06-18 16:02","market":"us","language":"en","title":"Orphazyme shares tumbled more than 60% in pre-market trading","url":"https://stock-news.laohu8.com/highlight/detail?id=1142916683","media":"Tiger Newspress","summary":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial foreca","content":"<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Orphazyme shares tumbled more than 60% in pre-market trading</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOrphazyme shares tumbled more than 60% in pre-market trading\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-18 16:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Orphazyme&nbsp;shares&nbsp;tumbled&nbsp;more&nbsp;than&nbsp;60% in pre-market&nbsp;trading.</p>\n<p><img src=\"https://static.tigerbbs.com/b722b82c7d6ab2a6fcc7364eb2517b7f\" tg-width=\"1293\" tg-height=\"628\" referrerpolicy=\"no-referrer\">Orphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.</p>\n<p>Orphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.</p>\n<p>As a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.</p>\n<p>\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.</p>\n<p>Orphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1142916683","content_text":"Orphazyme shares tumbled more than 60% in pre-market trading.\nOrphazyme slashed its financial forecasts on Friday after U.S. health regulators rejected its key drug candidate.\nOrphazyme said its application for FDA approval of arimoclomol, a treatment for genetic disorder Niemann-Pick disease type C, had not been successful.\nAs a result, it predicted revenue for the year would be lower than previously expected and its operating loss significantly wider, forcing the company to cut costs.\n\"Orphazyme has no money and no substantial projects ... Investors have put their money into a completely unrealistic scenario driven by 'meme tendencies',\" broker Nordnet wrote in a note to clients.\nOrphazyme, which is listed in Copenhagen and New York, now expects an operating loss of 670-700 million crowns ($107-$112 million) in 2021, against a previous forecast for a loss of 100-150 million crowns.","news_type":1,"symbols_score_info":{"ORPH":0.9}},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":121285710,"gmtCreate":1624465639130,"gmtModify":1631890740866,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"Nioo","listText":"Nioo","text":"Nioo","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/121285710","repostId":"1145825451","repostType":4,"isVote":1,"tweetType":1,"viewCount":2235,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":166664632,"gmtCreate":1624006870226,"gmtModify":1631892937482,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"like n comment!","listText":"like n comment!","text":"like n comment!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/166664632","repostId":"2144005727","repostType":4,"isVote":1,"tweetType":1,"viewCount":390,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":692251955,"gmtCreate":1641003795174,"gmtModify":1641003795174,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"nice","listText":"nice","text":"nice","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/692251955","repostId":"2195448557","repostType":4,"isVote":1,"tweetType":1,"viewCount":2601,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":129027708,"gmtCreate":1624346334604,"gmtModify":1631890740882,"author":{"id":"3573902637171983","authorId":"3573902637171983","name":"TehTarik","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":11,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3573902637171983","authorIdStr":"3573902637171983"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/129027708","repostId":"1186855284","repostType":4,"repost":{"id":"1186855284","kind":"news","pubTimestamp":1624345153,"share":"https://www.laohu8.com/m/news/1186855284?lang=&edition=full","pubTime":"2021-06-22 14:59","market":"us","language":"en","title":"If You Thought These 2 Big Nasdaq Winners Were Done, Think Again","url":"https://stock-news.laohu8.com/highlight/detail?id=1186855284","media":"Motley Fool","summary":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock mark","content":"<blockquote>\n On a strong day for the Nasdaq, two highfliers stood out.\n</blockquote>\n<p>Volatility has returned to the stock market, but finally, the<b>Nasdaq Composite</b>(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq&nbsp; was higher by three-quarters of a percent.</p>\n<p>It wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies like<b>Moderna</b>(NASDAQ:MRNA)and<b>BioNTech</b>(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.</p>\n<p><b>More moves for Moderna and BioNTech</b></p>\n<p>Shares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.</p>\n<p>The general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.</p>\n<p>In addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech and<b>Pfizer</b>(NYSE:PFE)for more vaccine doses as well.</p>\n<p>More broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.</p>\n<p><b>Will existing vaccines be enough?</b></p>\n<p>The biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.</p>\n<p>For the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.</p>\n<p>If you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>If You Thought These 2 Big Nasdaq Winners Were Done, Think Again</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIf You Thought These 2 Big Nasdaq Winners Were Done, Think Again\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-22 14:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"MRNA":"Moderna, Inc.","BNTX":"BioNTech SE"},"source_url":"https://www.fool.com/investing/2021/06/21/if-you-thought-big-nasdaq-winners-done-think-again/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1186855284","content_text":"On a strong day for the Nasdaq, two highfliers stood out.\n\nVolatility has returned to the stock market, but finally, theNasdaq Composite(NASDAQINDEX:^IXIC)is starting to make waves once again. The tech-heavy index is making a run toward all-time highs, trading within 1% of its high-water mark on Monday afternoon. As of just before 2 p.m. EDT today,the Nasdaq  was higher by three-quarters of a percent.\nIt wasn't that long ago that investors figured that stocks of COVID-19 vaccine manufacturers had already seen their best days. Companies likeModerna(NASDAQ:MRNA)andBioNTech(NASDAQ:BNTX)had seen their share prices start to give up ground as many believed that a vaccinated world would eventually cause revenue and profits to dry up for the vaccine makers. Now, though, it's becoming increasingly clear that the two companies could well have a much brighter future than many had thought.\nMore moves for Moderna and BioNTech\nShares of the vaccine manufacturers were among the leaders on the Nasdaq today. Moderna's gains amounted to more than 5%, while BioNTech boasted gains of 6% or more on the day.\nThe general sentiment toward BioNTech and Moderna has been positive because ofjust how effective their vaccines have been. Last month, the U.S. Centers for Disease Control and Prevention released the latest figures on efficacy for the messenger-RNA-based vaccines from the two companies. Data from real-life use showed a reduction in infection risks of 91%. Those who got infected had a 60% lower risk of showing symptoms, and they spent on average six days fewer being sick and two days fewer stuck in bed recovering.\nIn addition, the companies have benefited from sustained demand for COVID vaccines from countries around the world. On Monday,BioNTech said that it had received provision approvalof its vaccine from regulators in New Zealand. Over the weekend, the government of the Philippines announced a 40-million-dose agreement with BioNTech andPfizer(NYSE:PFE)for more vaccine doses as well.\nMore broadly, some health officials have started talking about the potential need for vaccine booster shots. It's uncertain at this point whether and how quickly antibody levels from initial vaccinations decline, and so it's entirely possible that even those who've already received vaccinations could need additional doses in the future. From a business standpoint, that would create even further demand for Moderna and BioNTech that could dramatically lengthen the expected flow of revenue stemming from COVID vaccines.\nWill existing vaccines be enough?\nThe biggest threat on the COVID front comes from the potential for the virus to mutate into more-dangerous variants. Already, theDelta varianthas proved to be more easily transmitted among infected patients and with more-severe health impacts. Future variants could prove even more problematic, and there's no guarantee that existing vaccines will provide protection against them all.\nFor the most part, both Moderna's and BioNTech's stock prices seem to reflect little expectation of success beyond the current COVID vaccine products. Yet if anything, COVID has proved that the broader-based investing thesis behind mRNA-based treatment development is sound. Both companies have plans for vaccines and other treatments for a wider variety of different medical conditions, and success anywhere on that front could provide the positive surprise investors need to gain confidence in the long-term futures of these stocks.\nIf you made the mistake of thinking that COVID vaccine stocks would be done once much of the U.S. population had been vaccinated, you aren't alone. But you might be surprised at how much staying power BioNTech and Moderna could have -- especially if a few things end up working out in their favor.","news_type":1,"symbols_score_info":{"BNTX":0.9,"MRNA":0.9}},"isVote":1,"tweetType":1,"viewCount":1446,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"lives":[]}